Nu.Q Biomarkers Study Reports Elevated Nucleosome Levels in Trauma Patients
A clinical study in Shock found that Nu.Q H3.1 and H3R8 Citrulline were significantly elevated in 674 trauma patients, especially those who developed VTE. The findings point to potential clinical utility for trauma care and support commercialization of Nu.Q NETs.
A clinical study published in Shock reported that nucleosome levels, specifically Nu.Q® H3.1 and H3R8 Citrulline, are significantly elevated in 674 trauma patients post-injury. The elevations were particularly seen in those who develop Venous Thromboembolism (VTE), indicating the potential clinical utility of these biomarkers in trauma care.
The study underscores the clinical challenge of identifying reliable biomarkers in trauma patients, especially in emergency and surgical settings. The findings suggest that these biomarkers could support early risk identification and targeted preventive strategies.
The peer-reviewed publication with the Mayo Clinic research team strongly supports efforts to commercialize Nu.Q® NETs. Researchers indicate that Nu.Q® NETs may assist clinicians and researchers in anticipating disease, guiding treatment decisions, and monitoring patients, with broad application potential across acute and chronic conditions.